glp-1 and osteoporosis AAOS: receptor agonist use increases five-year risk for GLP-1 weight loss drugs could

Inflammatory bowel disease (IBD) patients exhibit altered gut microbial diversity, such as an imbalance between Firmicutes and Bacteroidetes , an increase in Proteobacteria , and the depletion of Roseburia species [31, 32]

[2] Not to mention the potential unwanted side effects like nausea, constipation, bloating, and a concerningly low appetite make it hard to stick it out long-term

However, this is less likely if the body cannot synthesize glutathione from nutrients 21 , an ability that decreases with age

Depression is not commonly reported, though rare cases have prompted ongoing safety reviews

However, participants on semaglutide drank much less, with a higher proportion of zero heavy drinking days than those on placebo